Abstract
The prevalence of hypertension increases with age making it a significant health concern for older persons. Aging involves a range of physiological changes such as increases in arterial stiffness, widening pulse pressure, changes in renin and aldosterone levels, decreases in renal salt excretion, declining in renal function, changes in the autonomic nervous system sensitivity and function and changes to endothelial function all of which may not only affect blood pressure but may also affect individual response to pharmacotherapy used to manage hypertension and prevent end organ damage and other complications associated with poor blood pressure control.
Unlike many chronic conditions where there is limited evidence for management in older populations, there is good evidence regarding the management of hypertension in the elderly. The findings from multiple large, robust trials have provided a solid evidence-base regarding the management of hypertension in older adults, showing that reduction of blood pressure in older hypertensive populations is associated with reduced mortality and morbidity. Diuretics, agents action on the renin angiotensin system, beta blockers and calcium channel blockers have all been well studied in older populations both in view of the benefits associated with blood pressure lowering and the risks associated with associated adverse events. While all antihypertensive agents will lower blood pressure, when managing hypertension in older persons the choice of agent is dependent not only on the ability to lower blood pressure but also on the potential for harm with older persons. Understanding such potential harms in older populations is essential with older persons experiencing increased sensitivity to many of the adverse effects such as dizziness associated with the use of antihypertensive agents.
Despite the wealth of evidence regarding the benefits of managing hypertension in the old and very old, a significant proportion of older individuals with hypertension have suboptimal BP control. While there is good evidence supporting blood pressure lowering in older antihypertensive agents, these have not yet been optimally translated fully into clinical guidelines and clinical practice. There appear to be considerable differences between guidelines in terms of the guidance given to clinicians. Differences in interpretation of the evidence, as well as differences in study design and populations all contribute to differences in the guideline recommendations with respect to older populations, despite the strength of the underlying scientific evidence. Differences around who is considered “old” and what BP targets and management are considered appropriate may lead to confusion among clinicians and further contribute to the evidence-practice lag.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Alhawassi TM, Krass I, Bajorek BV, Pont LG (2014) A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging 9:2079–2086
Alhawassi TM, Krass I, Pont LG (2015) Prevalence, prescribing and barriers to effective management of hypertension in older populations: a narrative review. J Pharm Policy Pract 8:24
Barker WH, Mullooly JP, Linton KL (1998) Trends in hypertension prevalence, treatment, and control in a well-defined older population. Hypertension 31(1):552–559
Barreto SM, Passos VMA, Firmo JOA, Guerra HL, Vidigal PG, Lima-Costa MFF (2001) Hypertension and clustering of cardiovascular risk factors in a community in Southeast Brazil: the Bambuí Health and Ageing Study. Arq Bras Cardiol 77(6):576–581
Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N et al (1999) Patient risk factors for adverse drug events in hospitalized patients. Arch Intern Med 159(21):2553–2560
Beaglehole R, Ebrahim S, Reddy S, Voûte J, Leeder S (2008) Prevention of chronic diseases: a call to action. Lancet 370(9605):2152–2157
Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J et al (2012) Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 344
Bond C, Raehl CL (2006) Adverse drug reactions in United States hospitals. Pharmacotherapy 26(5):601–608
Bromfield SG, Bowling CB, Tanner RM, Peralta CA, Odden MC, Oparil S et al (2014) Trends in hypertension prevalence, awareness, treatment, and control among US adults 80 years and Older, 1988–2010. J Clin Hypertens 16(4):270–276
Bulpitt C, Beckett N, Peters R, Leonetti G, Gergova V, Fagard R et al (2011) Blood pressure control in the Hypertension in the Very Elderly Trial (HYVET). J Hum Hypertens 26(3):157–163
Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH (2013) The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporos Int 24(10):2649–2657
Callisaya ML, Sharman JE, Close J, Lord SR, Srikanth VK (2014) Greater daily defined dose of antihypertensive medication increases the risk of falls in older people--a population-based study. J Am Geriatr Soc 62(8):1527–1533
Carretero OA, Oparil S (2000) Essential hypertension part I: definition and etiology. Circulation 101(3):329–335
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19):2560–2571
Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W (1985) Long-term surveillance for adverse effects of antihypertensive drugs. JAMA 253(22):3263–3268
Daar AS, Singer PA, Persad DL, Pramming SK, Matthews DR, Beaglehole R et al (2007) Grand challenges in chronic non-communicable diseases. Nature 450(7169):494–496
Dahlöf BHL, Lindholm L, Schersten B, Ekbom T, Wester P (1991) Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 338(8778):1281–1285
Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS et al (2014) The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Canadian J Cardiol 30(5):485–501
Davies EC, Green CF, Mottram DR, Pirmohamed M (2007) Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf 2(1):79–87
Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M (2009) Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 4(2):e4439
Department of Economic and Social Affairs United Nations (2002) World population ageing: 1950–2050. UN
Devlin G (2010) Women and elderly: subgroups under-represented in clinical trials. Curr Opin Cardiol 25(4):335–339
Dharmarajan TS, Dharmarajan L (2015) Tolerability of antihypertensive medications in older adults. Drugs Aging 32(10):773–796
Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356(9237):1255–1259
Fagard RH (2002) Epidemiology of hypertension in the elderly. Am J Geriatr Cardiol 11(1):23–28
Falaschetti E, Mindell J, Knott C, Poulter N (2014) Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383(9932):1912–1919
Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC et al (2004) Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 52(8):1349–1354
Fliser D, Ritz E (1998) Relationship between hypertension and renal function and its therapeutic implications in the elderly. Gerontology 44(3):123–131
Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB et al (1997) Hemodynamic patterns of age-related changes in blood pressure The Framingham Heart Study. Circulation 96(1):308–315
Franklin SS, Jacobs MJ, Wong ND, Gilbert J, Lapuerta P (2001) Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 37(3):869–874
Gambassi G, Lapane K, Sgadari A, Landi F, Carbonin P, Hume A et al (1998) Prevalence, clinical correlates, and treatment of hypertension in elderly nursing home residents. Arch Intern Med 158(21):2377–2385
Gambert SR (1994) Who are the “elderly”? Geriatr Nephrol Urol 4(1):3–4
Gao Y, O’Caoimh R, Healy L, Kerins DM, Eustace J, Guyatt G et al (2013) Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open 3(7)
Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F et al (2013) Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309(11):1125–1135
Gribbin J, Hubbard R, Gladman JR, Smith C, Lewis S (2010) Risk of falls associated with antihypertensive medication: population-based case–control study. Age Ageing:afq092
Gribbin J, Hubbard R, Gladman J, Smith C, Lewis S (2011) Risk of falls associated with antihypertensive medication: self-controlled case series. Pharmacoepidemiol Drug Saf 20(8):879–884
Grimshaw JM, Russell IT (1993) Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 342(8883):1317–1322
Gross CP, Mallory R, Heiat A, Krumholz HM (2002) Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med 137(1):10–16
Grossman E, Messerli FH (2006) Long-term safety of antihypertensive therapy. Prog Cardiovasc Dis 49(1):16–25
Group JS (2008) Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 31(12):2115–2127
Hajjar I, Kotchen TA (2003) Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 290(2):199–206
Halter JB (2009) Hazzard’s geriatric medicine and gerontology. McGraw-Hill Companies
Hansson LLL, Ekbom T, Dahlöf B, Lanke J, Scherstén B et al (1999) Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354(9192):1751–1756
Heiat A, Gross CP, Krumholz HM (2002) Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 162(15):1682–1688
Huebschmann AD, Bublitz C, Anderson RJ (2006) Are hypertensive elderly patients treated differently? Clin Interven Aging 1(3):289
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5):507–520
Jaques H, National Institute for H, Clinical E (2013) NICE guideline on hypertension. Eur Heart J 34(6):406–408
Kannel WB, Gordan T (1978) Evaluation of cardiovascular risk in the elderly: the Framingham study. Bull N Y Acad Med 54(6):573–591
Kirkwood TB, Austad SN (2000) Why do we age? Nature 408(6809):233–238
Kleman M, Dhanyamraju S, DiFilippo W (2013) Prevalence and characteristics of pseudohypertension in patients with “resistant hypertension”. J Am Soc Hypertens 7(6):467–470
Kumar J (2013) Epidemiology of hypertension. Clinical Queries. Nephrology 2(2):56–61
Larochelle P, Tobe SW, Lacourcière Y (2014) β-blockers in hypertension: studies and meta-analyses over the years. Can J Cardiol 30(5):S16–S22
Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15):1200–1205
Lee DS, Goeres LM (2015) Higher antihypertensive dose increases risk of falls in older people. Evid Based Nurs 18(3):96
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al (2013) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2224–2260
Lloyd-Jones DM, Evans JC, Levy D (2005) Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 294(4):466–472
Luehr DWT, Burke R, Dohmen F, Hayes R, Johnson M, Kerandi H, Margolis K, Marshall M, O’Connor P, Pereira C, Reddy G, Schlichte A, Schoenleber M (2012) Hypertension diagnosis and treatment. Institute for Clinical Systems Improvement [Internet]. Updated November 2012. Available from: http://bit.ly/Hypertension1112
Mackey RH, Sutton-Tyrrell K, Vaitkevicius PV, Sakkinen PA, Lyles MF, Spurgeon HA et al (2002) Correlates of aortic stiffness in elderly individuals: a subgroup of the Cardiovascular Health Study. Am J Hypertens 15(1):16–23
Maclure M, Dormuth C, Naumann T, McCormack J, Rangno R, Whiteside C et al (1998) Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia. Lancet 352(9132):943–948
MacMahon SW, Blacket RB, Macdonald GJ, Hall W (1984) Obesity, alcohol consumption and blood pressure in Australian men and women the National Heart Foundation of Australia Risk Factor Prevalence Study. J Hypertens 2(1):85–91
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219
Mann SJ (1992) Systolic hypertension in the elderly: pathophysiology and management. Arch Intern Med 152(10):1977–1984
Masoro EJ, Austad SN (2006) Handbook of the biology of aging. Academic press
Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11):e442
Menotti A, Lanti M, Kafatos A, Nissinen A, Dontas A, Nedeljkovic S et al (2004) The role of a baseline casual blood pressure measurement and of blood pressure changes in middle age in prediction of cardiovascular and all-cause mortality occurring late in life: a cross-cultural comparison among the European cohorts of the Seven Countries Study. J Hypertens 22(9):1683–1690
Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA et al (2004) Changes in arterial stiffness and wave reflection with advancing age in healthy men and women the Framingham Heart Study. Hypertension 43(6):1239–1245
Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J (1997) The effects of initial drug choice and comorbidity on antihypertensive therapy compliance* results from a population-based study in the elderly. Am J Hypertens 10(7):697–704
Moore N, Lecointre D, Noblet C, Mabille M (1998) Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 45(3):301–308
Moser M (1998) Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA 279(22):1813–1816
Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349(9064):1498–1504
Musini VM, Tejani AM, Bassett K, Wright JM (2009) Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev 2009(4):CD000028
National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee) (2010) Guide to management of hypertension 2008. Updated December 2010. Accessed via https://heartfoundation.org.au/images/uploads/publications/HypertensionGuidelines2008to2010Update.pdf on April 15, 2016
Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23):2981–2997
Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K et al (2010) Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 56(2):196–202
Olsen H, Klemetsrud T, Stokke HP, Tretli S, Westheim A (1999) Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Blood Press 8(2):94–101
Onder G, Gambassi G, Landi F, Pedone C, Cesari M, Carbonin P et al (2001) Trends in antihypertensive drugs in the elderly: the decline of thiazides. J Hum Hypertens 15(5):291–297
Onder G, Pedone C, Landi F, Cesari M, Della Vedova C, Bernabei R et al (2002) Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 50(12):1962–1968
Pahor M, Carbonin P, Guralnik J, Havlik R, Furberg C (1996a) Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 347(9008):1061–1065
Pahor M, Guralnik JM, Ferrucci L, Corti M-C, Salive ME, Cerhan JR et al (1996b) Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348(9026):493–497
Parving H-H, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367(23):2204–2213
Perry HM Jr, Smith WM, McDonald RH, Black D, Cutler JA, Furberg CD et al (1989) Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke 20(1):4–13
Pimenta E, Oparil S (2012) Management of hypertension in the elderly. Nat Rev Cardiol 9(5):286–296
Pinto E (2007) Blood pressure and ageing. Postgrad Med J 83(976):109–114
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456):15–19
Prencipe M, Casini A, Santini M, Ferretti C, Scaldaferri N, Culasso F (2000) Prevalence, awareness, treatment and control of hypertension in the elderly: results from a population survey. J Hum Hypertens 14(12):825–830
Primatesta P, Poulter NR (2004) Hypertension management and control among English adults aged 65 years and older in 2000 and 2001. J Hypertens 22(6):1093–1098
Prince MJ, Ebrahim S, Acosta D, Ferri CP, Guerra M, Huang Y et al (2012) Hypertension prevalence, awareness, treatment and control among older people in Latin America, India and China: a 10/66 cross-sectional population-based survey. J Hypertens 30(1):177–187
Psaty BM, Koepsell TD, Yanez ND, Smith NL, Manolio TA, Heckbert SR et al (1995) Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992: an effect of the major clinical trials on clinical practice? JAMA 273(18):1436–1438
Psaty BM, Manolio TA, Smith NL, Heckbert SR, Gottdiener JS, Burke GL et al (2002) Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med 162(20):2325–2332
Rai GS, Mulley GP (2007) Elderly medicine: a training guide. Elsevier Health Sciences
Rejnmark L (2013) The ageing endocrine system: fracture risk after initiation of antihypertensive therapy. Nat Rev Endocrinol 9(4):189–190
Rende P, Paletta L, Gallelli G, Raffaele G, Natale V, Brissa N et al (2013) Retrospective evaluation of adverse drug reactions induced by antihypertensive treatment. J Pharmacol Pharmacotherap 4(Suppl1):S47
Rodriguez-Roca GC, Llisterri JL, Prieto-Diaz MA, Alonso-Moreno FJ, Escobar-Cervantes C, Pallares-Carratala V et al (2013) Blood pressure control and management of very elderly patients with hypertension in primary care settings in Spain. Hypertens Res 37(2):166–171
Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B et al (2015) Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs 29(2):113–130
Sato I, Akazawa M (2013) Polypharmacy and adverse drug reactions in Japanese elderly taking antihypertensives: a retrospective database study. Drug Healthcare Patient Saf 5:143–150
Schäfer H-H, De Villiers JN, Sudano I, Dischinger S, Theus G-R, Zilla P et al (2012) Recommendations for the treatment of hypertension in the elderly and very elderly–a scotoma within international guidelines. Swiss Med Wkly Epub
Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M et al (2014) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 37(4):253–387
Spranger CB, Ries AJ, Berge CA, Radford NB, Victor RG (2004) Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med 117(1):14–18
Stas S, Appesh L, Sowers J (2006) Metabolic safety of antihypertensive drugs: myth versus reality. Current Hypertens Rep 8(5):403–408
Svetkey LP, George LK, Tyroler HA, Timmons PZ, Burchett BM, Blazer DG (1996) Effects of gender and ethnic group on blood pressure control in the elderly. Am J Hypertens 9(6):529–535
Talbot J, Waller P (2004) Stephens’ detection of new adverse drug reactions. Wiley, New York
The World Health Organisation (2016) Projections of mortality and causes of death, 2015 and 2030. Accessed via http://www.who.int/healthinfo/global_burden_disease/projections/en/on 15 April 2016
Tinetti ME, Inouye SK, Gill TM, Doucette JT (1995) Shared risk factors for falls, incontinence, and functional dependence. Unifying the approach to geriatric syndromes. JAMA 273(17):1348–1353
Tinetti ME, Han L, Lee DS, McAvay GJ, Peduzzi P, Gross CP et al (2014) Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med 174(4):588–595
Trenkwalder P, Ruland D, Stender M, Gebhard J, Trenkwalder C, Lydtin H et al (1994) Prevalence, awareness, treatment and control of hypertension in a population over the age of 65 years: results from the Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly (STEPHY). J Hypertens 12(6):709
Triantafyllou A, Douma S, Petidis K, Doumas M, Panagopoulou E, Pyrpasopoulou A et al (2010) Prevalence, awareness, treatment and control of hypertension in an elderly population in Greece. Rural Remote Health 10(2):1225
Tu K, Campbell NR, Chen Z, McAlister FA (2006) Thiazide diuretics for hypertension: prescribing practices and predictors of use in 194,761 elderly patients with hypertension. Am J Geriatr Pharmacother 4(2):161–167
Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F et al (2008) Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336(7653):1121–1123
Van Kraaij D, Jansen R, Gribnau F, Hoefnagels W (1998) Loop diuretics in patients aged 75 years or older: general practitioners’ assessment of indications and possibilities for withdrawal. Eur J Clin Pharmacol 54(4):323–327
Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB et al (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 287(8):1003–1010
Wallace SM, McEniery CM, Mäki-Petäjä KM, Booth AD, Cockcroft JR, Wilkinson IB (2007) Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension 50(1):228–233
Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al (2014) Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 32(1):3–15
Weinberger MH (1996) Salt sensitivity of blood pressure in humans. Hypertension 27(3):481–490
Wester K, Jonsson AK, Spigset O, Druid H, Hagg S (2008) Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 65(4):573–579
White SM (2010) Including the very elderly in clinical trials. Anaesthesia 65(8):778–780
White TJ, Arakelian A, Rho JP (1999) Counting the costs of drug-related adverse events. Pharmacoeconomics 15(5):445–458
Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL et al (2003) A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348(7):583–592
Yang G, Kong L, Zhao W, Wan X, Zhai Y, Chen LC et al (2008) Emergence of chronic non-communicable diseases in China. Lancet 372(9650):1697–1705
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this chapter
Cite this chapter
Pont, L., Alhawassi, T. (2016). Challenges in the Management of Hypertension in Older Populations. In: Islam, M.S. (eds) Hypertension: from basic research to clinical practice. Advances in Experimental Medicine and Biology(), vol 956. Springer, Cham. https://doi.org/10.1007/5584_2016_149
Download citation
DOI: https://doi.org/10.1007/5584_2016_149
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-44250-1
Online ISBN: 978-3-319-44251-8
eBook Packages: MedicineMedicine (R0)